FAIRFIELD, N.J., June 15 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced the launch of Peranex(TM) HC Cream (Hydrocortisone Acetate 2% -- Lidocaine HCl 2%) by the Company's Kenwood Therapeutics division. Peranex(TM) HC Cream is the first product in a new line of anorectal treatments used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area.
Peranex(TM) HC Cream offers patients a complete way to treat hemorrhoids. Each Peranex(TM) HC prescription contains 12 full days of therapy with 24 single-use tubes, pre-application wipes, 24 flushable cleansing wipes, and patient information about hemorrhoids.
"We are very enthusiastic about the introduction of the new Peranex(TM) HC brand," commented Daniel Glassman, President and CEO of Bradley Pharmaceuticals. "Part of our business strategy is to offer new products and line extensions that add value to both patients and physicians. This brand alternative offers proven efficacy, more therapy and additional components that will help make dealing with these uncomfortable conditions easier. We expect to receive a positive reception from both physicians and their patients."
Peranex(TM) HC Cream will be promoted to gastroenterologists and OB/GYN physicians and is currently available from wholesalers.
Important Product Safety Information About Peranex(TM) HC Cream:
Peranex(TM) HC Cream is contraindicated for tuberculous or fungal lesions, skin vaccinia, varicella or acute herpes simplex. Peranex(TM) HC Cream should be used with caution by patients with impaired liver function, significant liver disease, the elderly, very ill, and patients taking Class I anti- arrhythmic drugs. Transient stinging or burning from open areas of skin, or transient lightening or redness of the skin may occur during or immediately after use. For external use only.
For additional important information about Peranex(TM) HC Cream, please request full prescribing information by contacting Bradley Pharmaceuticals.
Please visit the Bradley Pharmaceuticals web site at: http://www.bradpharm.com/.
About Bradley Pharmaceuticals, Inc.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley's success is based upon its core strengths in marketing and sales, which enable the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley's marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Safe Harbor for Forward-Looking Statements:
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as Bradley's plans to in-license, develop and launch new and enhanced products with long-term intellectual property protection or other significant barriers to market entry, sales and earnings estimates, other predictions of financial performance, timing of payments on indebtedness, launches by Bradley of new products, market acceptance of Bradley's products, and the achievement of initiatives to enhance corporate governance and long-term shareholder value. Forward-looking statements are based on Bradley's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley's control. These risks and uncertainties include Bradley's ability to: launch VEREGEN(TM) at the end of 2007; predict the safety and efficacy of these products in a commercial setting; estimate sales; maintain adequate inventory levels; implement the returns and inventory optimization plan timely, if at all; reduce product returns; comply with the restrictive covenants under its credit facility; refinance its credit facility; access the capital markets on attractive terms or at all; favorably resolve the pending SEC informal inquiry; maintain or increase sales of its products; or effectively react to other risks and uncertainties described from time to time in Bradley's SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action and shareholder derivative lawsuits), government regulation and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley's products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
